Introduction
Bullous pemphigoid (BP) is the most common cutaneous autoimmune blistering disease. It typically affects elderly patients and is associated with significant rates of morbidity and mortality. 1 Mucosal involvement is usually present in about 20-30% of patients. 1 Most patients with BP have circulating autoantibodies directed against one of two hemidesmosomal proteins (BP180 and BP230). 2 Antibodies directed against the extracellular NC16A domain of BP180 protein have been shown to play a relevant role in the pathogenicity of this disease. 2 Although in the vast majority of patients no causative agent is identified, in rare instances development of the disease has been linked to the use of certain drugs. 3 This drug-induced variant of BP usually shares common clinical, histopathological, and immunofluorescence findings with conventional BP. 3 The intrinsic pathogenic mechanisms underlying this peculiar drug-related BP subtype are unknown, and only few studies that characterize the epitope specificities have been performed. 4 Oral dipeptidyl peptidase-4 (DPP-4) inhibitors, so-called glip- ELISA for BP180 and BP230 ELISA analysis was performed for all patients. IgG antibodies directed against BP180 and BP230 proteins were evaluated using commercial kits (MBL International, Nagoya, Japan). The ELISA system for BP180 was specific for the NC16A domain.
The results of the ELISA assays for BP180 were retrieved from the patients' reports, whereas the results of the ELISA for BP230 were obtained from frozen serum samples stored at À80°C.
IB studies
All of the IB studies were performed in Kurume University
School of Medicine (Japan) using frozen serum samples stored at À80°C at the patients' respective hospitals.
IB of normal human epidermal extracts was performed according to the method described by Sugi et al. 11 For IB containing a recombinant form of BP180 NC16A, a fusion protein was prepared as previously described by Matsumura et al.
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In addition, IB using a recombinant protein corresponding to the carboxy-terminal (C-terminal) domain of BP180 was carried out. This fusion protein was obtained via the technique described by Nie et al.
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IB assays with concentrated supernatants of HaCaT cells culture medium for the LAD-1 120 kDa fragment, normal human dermal extracts, and purified human laminin 332 (laminin 5)
were also carried out following the methods previously described by Ishii et al. and Hisamatsu et al., respectively. [14] [15] [16] In one patient, only IB studies with normal human epidermal and dermal extracts could be conducted due to an insufficient amount of serum sample.
Results

Patient demographics
Eight patients (4 females and 4 males), with a mean age of 80 years, were included (Table 1 Response to treatment Treatment with the DPP-4 inhibitor was stopped shortly after diagnosis of BP in all patients except two. Treatment of one patient (No. 5) had been suspended 2 months before consultation and 4 months after the onset of symptoms. In another patient (No. 7), medication was discontinued 9 months after the first consultation.
Three patients were treated with topical clobetasol propionate alone following the regimen proposed by Joly et al.
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The remaining patients received oral systemic treatments at low doses: dapsone (three patients) and cyclophosphamide (one patient), along with low doses of corticosteroids (0.5 mg/ kg per day) on a tapering-off regimen (four patients) ( Table 1) .
Clinical remission was achieved after a median time of Table 1 Clinical characteristics of the patients and results of the ELISA and immunoblot studies Antibody profile ELISA assays for BP180 were positive in six patients (75%) at diagnosis, although antibody titres were low in one of them (Table 1) . In one patient, the ELISA was negative at diagnosis None of the patients had IgA-class reactivity.
None of the serum samples reacted with normal human dermal extracts or purified laminin 332.
Discussion
Drug-induced pemphigoid is a variant of classic BP that develops following the oral or topical administration of certain drugs.
Since first being reported in 1970, more than 50 different drugs have been implicated, a number that is constantly increasing with the introduction of new medications. 3 However, in casecontrol studies, only two of these drugs (neuroleptics and aldosterone antagonists) have demonstrated a statistically significant association with BP. 18, 19 In fact, identifying the responsible drug can often prove quite difficult, since many BP patients receive multiple medications. 3, 18 In addition, given the considerable morbidity and mortality rates of this disease, re-challenge with the suspected therapy in question is not feasible. As in our patients, the time periods described in the literature from the start of the drug intake to the onset of symptoms are quite variable. In their study, Bene et al. reported a median time of 10 months, with a range from 8 days to 37 months. 8 Overall,
clinical symptoms promptly resolved in our patients after the discontinuation of gliptins, without the need of any further systemic treatment (three patients) or just requiring systemic drugs at low doses and over short periods of time (four patients). This is in agreement with previous reports of DI-BP. [5] [6] [7] In three of our patients, sustained clinical remission was documented during a follow-up period of at least 1 year after discontinuation of anti-BP therapy.
Recently, Izumi et al. Importantly, IgG reactivity to LAD-1 (86%) in our series was more frequent than expected according to the previously published prevalence in BP (27-67%). [24] [25] [26] When reviewing the literature, we have only found four BP patients, apart from our two cases and Izumi's cases, showing antibodies exclusively against the LAD-1 fraction. [27] [28] [29] [30] Remarkably, three of these patients had noninflammatory BP, and two of them were being treated with DPP-4 inhibitors.
Contrary to Izumi et al.'s cases, which showed a negative reactivity against the C-terminal region of BP180, 50% of our cases reacted with it, a figure higher than expected according to previous studies on BP (23.5-33%). 4, 22, 31 The main limitations of our study are the small number of patients, the absence of a control group and, because of ethical 
